CD4 T-cell immunotherapy targeting MAGE-A3 is safe, and shows early clinical responses

New investigational targeted therapeutic, entrectinib, shows early promise

Galectins in tumour immunity

Treatment of relapsed myeloma with novel targeted and immune therapies

Targeting T regs in tumours

Multiplex IHC as biomarkers for cancer immunotherapy

Direct activation of STING in the tumour microenvironment leads to potent and systemic tumour regression and immunity

Successes and challenges in designing combination immunotherapy clinical trials for breast cancer

Breast cancer risk prediction models improved by adding multiple biological markers of risk

Physical activity may improve prostate cancer prognosis

Inflammatory microenvironment regulates colorectal cancer progression

Mechanisms of immune escape in non-Hodgkin lymphoma